CryoLife Enters into Worldwide Distribution and Manufacturing Agreements
CryoLife, Inc. (NYSE: CRY) announced today that it has entered into a worldwide distribution agreement and a manufacturing agreement with Starch Medical Inc. (SMI) of San Jose, California for PerClot®, a novel polysaccharide hemostatic agent used in surgery.
The U.S. hemostatic market is estimated to be $732 million in 2010 growing to approximately $1.1 billion in 2014, while the European market is estimated to be $279 million in 2010 growing to approximately $430 million in 2014.(1)
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.